Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.
Journal article
Sallman DA. et al, (2023), J Clin Oncol
Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns (Nature Communications, (2020), 11, 1, (728), 10.1038/s41467-019-13825-8)
Journal article
Jiao W. et al, (2022), Nature Communications, 13
Author Correction: Combined burden and functional impact tests for cancer driver discovery using DriverPower (Nature Communications, (2020), 11, 1, (734), 10.1038/s41467-019-13929-1)
Journal article
Shuai S. et al, (2022), Nature Communications, 13
Author Correction: Divergent mutational processes distinguish hypoxic and normoxic tumours (Nature Communications, (2020), 11, 1, (737), 10.1038/s41467-019-14052-x)
Journal article
Bhandari V. et al, (2022), Nature Communications, 13
Author Correction: Genomic footprints of activated telomere maintenance mechanisms in cancer (Nature Communications, (2020), 11, 1, (733), 10.1038/s41467-019-13824-9)
Journal article
Sieverling L. et al, (2022), Nature Communications, 13
Author Correction: High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations (Nature Communications, (2020), 11, 1, (736), 10.1038/s41467-019-13885-w)
Journal article
Zhang Y. et al, (2022), Nature Communications, 13
Author Correction: Inferring structural variant cancer cell fraction (Nature Communications, (2020), 11, 1, (730), 10.1038/s41467-020-14351-8)
Journal article
Cmero M. et al, (2022), Nature Communications, 13
Author Correction: Pathway and network analysis of more than 2500 whole cancer genomes (Nature Communications, (2020), 11, 1, (729), 10.1038/s41467-020-14367-0)
Journal article
Reyna MA. et al, (2022), Nature Communications, 13
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
Journal article
Daver NG. et al, (2022), Cancer Discovery, OF1 - OF14
A Phase 3, Randomized Trial of Magrolimab in Combination With Venetoclax and Azacitidine in Previously Untreated Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy (ENHANCE-3)
Conference paper
Daver N. et al, (2022), AMERICAN JOURNAL OF HEMATOLOGY, 97, S5 - S5
A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine in Previously Untreated Patients With TP53-Mutant Acute Myeloid Leukemia
Conference paper
Daver N. et al, (2022), AMERICAN JOURNAL OF HEMATOLOGY, 97, S5 - S6
AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions
Journal article
Daver N. et al, (2022), Clinical Lymphoma, Myeloma and Leukemia, 22, S231 - S232
AML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies
Journal article
Lachowiez C. et al, (2022), Clinical Lymphoma, Myeloma and Leukemia, 22, S240 - S241
AML-399 A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined With Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia (AML)
Journal article
Vyas P. et al, (2022), Clinical Lymphoma, Myeloma and Leukemia, 22
AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial
Journal article
DiNardo CD. et al, (2022), Clinical Lymphoma, Myeloma and Leukemia, 22, S249 - S250
AML-464 Tolerability and Efficacy of the First-In-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results
Journal article
Daver N. et al, (2022), Clinical Lymphoma, Myeloma and Leukemia, 22, S253 - S254
Magrolimab in Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes: 5F9005 Phase 1b Study Results
Conference paper
Sallman DA. et al, (2022), AMERICAN JOURNAL OF HEMATOLOGY, 97, S20 - S21
MDS-445 Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results
Journal article
Sallman D. et al, (2022), Clinical Lymphoma, Myeloma and Leukemia, 22, S314 - S315
MDS-482 Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS)
Journal article
Chen J. et al, (2022), Clinical Lymphoma, Myeloma and Leukemia, 22, S317 - S318
A tubulin binding molecule drives differentiation of acute myeloid leukemia cells.
Journal article
Jackson TR. et al, (2022), iScience, 25